<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572843</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 16/14</org_study_id>
    <secondary_id>000001480</secondary_id>
    <nct_id>NCT02572843</nct_id>
  </id_info>
  <brief_title>Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to demonstrate that the addition of neoadjuvant and adjuvant
      immunotherapy (with the anti-PD-L1 antibody MEDI4736) to standard neoadjuvant chemotherapy
      (with cisplatin/docetaxel) in primary resectable stage IIIA(N2) NSCLC is efficacious and
      feasible.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite multimodal therapy, the cure rate of patients with stage IIIA NSCLC is poor and
      therapy outcome failed to improve during the past years. The addition of immunotherapy with
      the anti-PD-L1 antibody MEDI4736 as a novel treatment modality has the potential to improve
      the outcome without adding substantial toxicity to an otherwise intensive multimodality
      treatment, as MEDI4736 has been generally well tolerated. Based on the current evidence on
      immune checkpoint inhibition, there is a strong rationale to test this novel treatment
      modality also in the curative setting in order to improve local tumor control and prevent
      distant metastasis to improve the cure rate in this patient population.

      The trial investigates the addition of pre- and post-operative immune checkpoint inhibition
      with MEDI4736 to the previously established standard of care for stage IIIA(N2) patients,
      which is based on the trials SAKK16/96 and SAKK16/00. Patients whose tumor is deemed
      resectable at diagnosis will receive 3 cycles (21 days each) of standard chemotherapy with
      cisplatin (100 mg/m2) / docetaxel (85 mg/m2), followed by 2 cycles (14 days each) of
      neoadjuvant immunotherapy with MEDI4736 750 mg. Following surgery, patients with complete
      resection (R0) of their tumor will be administered adjuvant treatment with MEDI4736 750 mg
      for up to one year or until recurrence, death, unacceptable toxicity or consent withdrawal
      (whichever occurs first). Patients with incomplete R1/R2 resection, including patients with
      extracapsular spread of mediastinal lymph node metastases, may undergo standard radiotherapy
      prior to adjuvant treatment with MEDI4736.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 11, 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at 12 months and at 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response (OR) after neoadjuvant chemotherapy</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OR after neoadjuvant immunotherapy</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological responses (pCR)</measure>
    <time_frame>at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs) (according to NCI CTCAE v4.0)</measure>
    <time_frame>at 12 months and at 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>NSCLC Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>MEDI4736</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whose tumor is deemed resectable at diagnosis will receive 3 cycles (21 days each) of standard chemotherapy with cisplatin/docetaxel followed by 2 cycles (14 days each) of neoadjuvant immunotherapy with MEDI4736 750 mg. Following surgery, patients with complete resection (R0) of their tumor will be administered adjuvant treatment with MEDI4736 750 mg for up to one year or until recurrence, death, unacceptable toxicity or consent withdrawal (whichever occurs first). Patients with incomplete R1/R2 resection, including patients with extracapsular spread of mediastinal lymph node metastases, may undergo standard radiotherapy prior to adjuvant treatment with MEDI4736.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI4736 (anti-PD-L1)</intervention_name>
    <description>fixed dosing 750 mg</description>
    <arm_group_label>MEDI4736</arm_group_label>
    <other_name>durvalumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent according to ICH-GCP regulations before patient registration
             and any protocol-related procedures.

          -  Pathologically proven NSCLC (adeno-, squamous-, large cell carcinoma or NSCLC not
             otherwise specified) irrespective of genomic aberrations or PD-L1 expression status.

          -  Tumor tissue is available for the mandatory translational research (preferably
             histology, cytology allowed).

          -  Tumor stage T1-3N2M0 (stage IIIA(N2)) according to the TNM classification, 7th
             edition, (October 2009). Mediastinal lymph node staging has to follow the process
             chart.

          -  Tumor is considered resectable based on a multidisciplinary tumor board decision made
             before neoadjuvant treatment. Resectable is when a complete resection can be achieved
             according to Rami-Porta {Rami-Porta, 2005 #88}.

          -  Measurable disease according to RECIST 1.1 criteria (non-nodal lesions ≥10 mm in
             longest diameter, lymph nodes ≥15 mm in short axis) by PET/CT with contrast enhanced
             CT-scan.

          -  WHO performance status 0-1.

          -  Age 18-75 years at time of registration.

          -  Appropriate lung function based on the ESTS guidelines {Brunelli, 2009 #19}:

               -  For pneumonectomy: FEV1 and DLCO ≥80%. If one of both &lt;80% an exercise test peak
                  VO2 &gt;75% or 20ml/kg/min is needed,

               -  For resection less than pneumonectomy (resection up to the calculated extent):
                  exercise test peak VO2 ≥35% or ≥10ml/kg/min, with predicted postoperative FEV1
                  and DLCO ≥ 30%.

          -  Adequate hematological values: hemoglobin ≥ 90 g/L, absolute neutrophils count ≥ 1.5 x
             109/L, platelets count ≥ 100 x 109/L.

          -  Adequate hepatic function: bilirubin ≤ 1.5 x ULN, AST/ALT ≤ 1.5 x ULN, AP ≤ 2.5 x ULN.

          -  Adequate renal function: calculated creatinine clearance ≥ 60 mL/min, according to the
             formula of Cockcroft-Gault.

          -  Women with child-bearing potential are using effective contraception are not pregnant
             or lactating and agree not to become pregnant during participation in the trial and
             during 90 days after the last treatment. A negative serum pregnancy test performed
             within 7 days before registration into the trial is required for all women with
             child-bearing potential. Men agree not to father a child during participation in the
             trial and during 90 days after the last treatment.

          -  Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including
             follow-up.

        Exclusion Criteria:

          -  Presence of any distant metastasis or N3 disease. Brain metastases have to be excluded
             by CT or MRI.

          -  Sulcus superior tumors (Pancoast tumors).

          -  Previous or concomitant malignancy within 5 years prior registration with the
             exception of adequately treated localized non-melanoma skin cancer or cervical
             carcinoma in situ.

          -  Any previous treatment for NSCLC.

          -  Any previous treatment with a PD-1 or PD-L1 inhibitor, including MEDI4736.

          -  Previous radiotherapy to the chest.

          -  Absolute contraindications for the use of corticosteroids as premedication.

          -  Concurrent treatment with other experimental drugs or other anti-cancer therapy,
             treatment in a clinical trial within 30 days prior to registration.

          -  Current or prior use of immunosuppressive medication within 28 days before the first
             dose of MEDI4736, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses (i.e. which must not exceed 10 mg/day
             of prednisone or an equivalent corticosteroid) and the premedication for chemotherapy.

          -  Severe or uncontrolled cardiac disease requiring treatment, congestive heart failure
             NYHA III or IV, unstable angina pectoris even if medically controlled, history of
             myocardial infarction during the last 3 months, serious arrhythmias requiring
             medication (with exception of atrial fibrillation or paroxysmal supraventricular
             tachycardia).

          -  Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3
             electrocardiograms (ECGs) using Bazett's Correction.

          -  Preexisting peripheral neuropathy (&gt; grade 1).

          -  Body weight less than 30 kg.

          -  Active autoimmune disease requiring systemic treatment within the past 3 months or a
             documented history of clinically severe autoimmune disease or a syndrome that requires
             systemic steroids or immunosuppressive agents. Exceptions: - Vitiligo or resolved
             childhood asthma/atopy - Hypothyroidism stable on hormone replacement or Sjorgen's
             syndrome

          -  Active or prior documented inflammatory bowel disease (e.g. Crohn's disease,
             ulcerative colitis).

          -  Known evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency
             virus (HIV) infection.

          -  History of primary immunodeficiency.

          -  History of allogeneic organ transplant.

          -  Known history of previous clinical diagnosis of tuberculosis.

          -  Receipt of live attenuated vaccination any time during trial therapy with MEDI4736 and
             within 30 days of receiving the last dose of MEDI4736.

          -  Any concomitant drugs contraindicated for use with MEDI4736: this includes systemic
             corticosteroids, methotrexate, azathioprine, and tumor necrosis factor (TNF)-α
             blockers. Any concomitant drugs contraindicated for use with the other trial drugs
             according to the locally approved product information.

          -  Known hypersensitivity to trial drugs (cisplatin and docetaxel), to the IMP or to any
             excipient.

          -  Any other serious underlying medical (e.g. uncontrolled diabetes mellitus, active
             uncontrolled infection, active gastric ulcer, uncontrolled seizures, severe hearing
             impairment), psychiatric, psychological, familial or geographical condition that, in
             the judgment of the investigator, may interfere with the planned staging, treatment
             and follow-up, affect patient compliance or place the patient at high risk from
             treatment-related complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sacha Rothschild, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corinne Rusterholz, PhD</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Wolf, Prof</last_name>
      <phone>+49 221 478-89050</phone>
      <email>juergen.wolf@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Jürgen Wolf, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Riera Knorrenschild, MD</last_name>
      <phone>+49 (06421) 58-62784</phone>
      <email>rierakno@med.uni-marburg.de</email>
    </contact>
    <investigator>
      <last_name>Jorge Riera Knorrenschild, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <state>Zurich</state>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donat Dürr, MD</last_name>
      <phone>+41 44 416 34 80</phone>
      <email>donat.duerr@triemli.zuerich.ch</email>
    </contact>
    <investigator>
      <last_name>Donat Dürr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolf-Dieter Janthur, MD</last_name>
      <phone>+41 62 838 55 80</phone>
      <email>wolf-dieter.janthur@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Wolf-Dieter Janthur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Waibel, MD</last_name>
      <phone>+41 (0)56 486 27 62</phone>
      <email>christine.waibel@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Christine Waibel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Claraspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Buess, MD</last_name>
      <phone>+41 (0)61 685 83 68</phone>
      <email>martin.buess@claraspital.ch</email>
    </contact>
    <investigator>
      <last_name>Martin Buess, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sacha Rothschild, MD</last_name>
      <phone>+41 61 265 25 25</phone>
      <email>sacha.rothschild@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Sacha Rothschild, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IOSI Ospedale Regionale di Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Froesch, MD</last_name>
      <phone>+41 (0)91 811 48 40</phone>
      <email>patrizia.froesch@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Patrizia Froesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Ochsenbein, Prof</last_name>
      <phone>+41 31 632 81 69</phone>
      <email>adrian.ochsenbein@sec.insel.ch</email>
    </contact>
    <investigator>
      <last_name>Adrian Ochsenbein, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Valais</name>
      <address>
        <city>Brig</city>
        <zip>3900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reinhard Zenhäusern, MD</last_name>
      <phone>+41 (0)27 604 36 60</phone>
      <email>reinhard.zenhaeusern@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Reinhard Zenhäusern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorenz M. Jost, MD</last_name>
      <phone>41-61-436-3636</phone>
      <email>lorenz.jost@ksbh.ch</email>
    </contact>
    <investigator>
      <last_name>Lorenz M. Jost, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mark, MD</last_name>
      <phone>+41 81 256 61 11</phone>
      <email>michael.mark@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Michael Mark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital Thurgau AG</name>
      <address>
        <city>Frauenfeld</city>
        <zip>CH-8500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Hopital Fribourgeois HFR</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Betticher, Prof</last_name>
      <phone>+41(0)26 426 72 40</phone>
      <email>daniel.betticher@h-fr.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Betticher, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Mach</last_name>
      <phone>+41 (0)22 372 98 81</phone>
      <email>nicolas.mach@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Nicolas Mach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CCAC Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Bohanes, MD</last_name>
      <phone>+41 (21) 646 79 94</phone>
      <email>pbohanes@bluewin.ch</email>
    </contact>
    <investigator>
      <last_name>Pierre Bohanes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire vaudois CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solange Peters, Prof</last_name>
      <phone>+41 79 556 01 92</phone>
      <email>solange.peters@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Solange Peters, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Gautschi, PD MD</last_name>
      <phone>+41 41 205 58 60</phone>
      <email>oliver.gautschi@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Oliver Gautschi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Früh, MD</last_name>
      <phone>+41 (0)71 494 63 25</phone>
      <email>martin.frueh@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Martin Früh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regionalspital</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rauch, MD</last_name>
      <phone>+41 33 226 26 45</phone>
      <email>daniel.rauch@spitalstsag.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Rauch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miklos Pless, Prof</last_name>
      <phone>41-52-266-2552</phone>
      <email>miklos.pless@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Miklos Pless, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden Onkozentrum Zürich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas von Briel, MD</last_name>
      <phone>+41 (0)44 387 21 11</phone>
      <email>vonbriel@onkozentrum.ch</email>
    </contact>
    <investigator>
      <last_name>Thomas von Briel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Britschgi, MD</last_name>
      <phone>+41 (44) 255 22 14</phone>
      <email>christian.britschgi@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Christian Britschgi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>lung cancer</keyword>
  <keyword>MEDI4736</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>anti-PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

